Vorapaxar in Patients With Diabetes Mellitus and Previous Myocardial Infarction: Findings From the Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events-TIMI 50 Trial

BACKGROUND—: Vorapaxar reduces cardiovascular death, myocardial infarction (MI), or stroke in patients with previous MI while increasing bleeding. Patients with diabetes mellitus (DM) are at high risk of recurrent thrombotic events despite standard therapy and may derive particular benefit from anti...

Descripción completa

Detalles Bibliográficos
Autores principales: Cavender, Matthew A., Scirica, Benjamin M., Bonaca, Marc P., Angiolillo, Dominick J., Dalby, Anthony J., Dellborg, Mikael, Morais, Joao, Murphy, Sabina A., Ophuis, Ton Oude, Tendera, Michal, Braunwald, Eugene, Morrow, David A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2015
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4365950/
https://www.ncbi.nlm.nih.gov/pubmed/25681464
http://dx.doi.org/10.1161/CIRCULATIONAHA.114.013774

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4365950/
https://www.ncbi.nlm.nih.gov/pubmed/25681464
http://dx.doi.org/10.1161/CIRCULATIONAHA.114.013774

Ejemplares similares